- Home
- NKTR
NKTR
Nektar Therapeutics
as 12-20-2024 3:40pm EST
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 247.9M | IPO Year: | 1994 |
| Target Price: | $4.00 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.47 - $1.93 | Next Earning Date: | 11-07-2024 |
| Revenue: | $93,137,000 | Revenue Growth: | 5.53% |
| Revenue Growth (this year): | 12.85% | Revenue Growth (next year): | -3.89% |
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Nov 19 '24 | Sell | $1.01 | 6,407 | $6,471.07 | 218,856 | |
| ROBIN HOWARD W | NKTR | President & CEO | Nov 19 '24 | Sell | $1.01 | 16,278 | $16,440.78 | 832,080 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Nov 19 '24 | Sell | $1.01 | 7,785 | $7,862.85 | 243,019 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
HC Wainwright Initiates Nektar Therapeutics at Buy With $6.50 Price Target
PR Newswire
15 days ago
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
PR Newswire
a month ago
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Simply Wall St.
a month ago
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
Simply Wall St.
a month ago
Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
a month ago
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
GuruFocus.com
a month ago
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook
Zacks
a month ago
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Compare NKTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.